{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089376","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.190997+00:00","generated_at":"2026-06-11T21:23:10.017707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q2 revenue $57M (-11% YoY), net loss $18.4M; FY guidance $233-243M","bullets":["Revenue $57.0M, down 11% YoY; net loss attributable to common $20.4M ($0.42/share) vs. $11.2M loss a year ago.","MVE China revenue fell 67% YoY ($5.8M decline); slower client ramps also hit Biopharma/Pharma segment.","Bioservices revenue rose 38% to $3.2M; commercial therapy revenue up 9.2% to $4.3M.","Adjusted EBITDA was -$1.5M, down $7.5M YoY from $6.0M; net loss widened to $18.4M from $9.2M.","FY2023 revenue guidance $233-243M; cash & short-term investments $504.7M at June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089376","json":"https://secwatch.observer/filing/0001104659-23-089376.json","markdown":"https://secwatch.observer/filing/0001104659-23-089376.md","text":"https://secwatch.observer/filing/0001104659-23-089376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/0001104659-23-089376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/tm2323346d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:23:10.017707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9df22306da5e2ce7ca600dad819336bb589666b","claim":"Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $57.0 million.","evidence_excerpt":"--- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2323346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2023 Financial Results § Second quarter revenue of $57 million, in line with previously announced preliminary results § Clinical trials supported by Cryoport increased to a record 668 global clinical trials by quarter end; a net increase of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923089376/0001104659-23-089376-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$57.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}